Methodology breakdown computing — it will appear here on its own.
BeOne Medicines, Ltd. American Depositary Receipt (ONC) is currently considered halal (Sharia-compliant), per our secondary compliance provider (last assessed 2026-08-12). See the full ratio breakdown and business-activity screen below for the reasoning.
Computing the full ratio and business-activity breakdown for ONC — this runs off the critical path so the page paints first. It will appear here on its own.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 41.30 | NEUTRAL |
| Stochastic %K (14) | 11.27 | BUY |
| CCI (20) | -162.84 | BUY |
| Williams %R (14) | -88.73 | BUY |
| MACD (12,26,9) | -4.79 | SELL |
| ROC (10) | -9.05 | SELL |
| Momentum (10) | -34.00 | SELL |
| EMA (10) | 356.04 | SELL |
| SMA (10) | 358.45 | SELL |
| EMA (20) | 355.97 | SELL |
| SMA (20) | 363.21 | SELL |
| EMA (30) | 351.02 | SELL |
| SMA (30) | 354.07 | SELL |
| EMA (50) | 340.49 | BUY |
| SMA (50) | 337.38 | BUY |
| EMA (100) | 326.91 | BUY |
| SMA (100) | 313.97 | BUY |
| EMA (200) | 325.89 | BUY |
| SMA (200) | 317.79 | BUY |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Biotechnology
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. The company has a agreement with U.S. government to expand access to innovative cancer medicines. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.
Background via Yahoo Finance — informational, not part of the verdict.
⚪ NEUTRAL — No Edge
Signals are mixed with no clear edge in either direction. Stand aside and wait for one more confluence factor.
Scores: 2 bullish / 1 bearish
Average — needs more confirmation before sizing up
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | BEARISH | 62 |
| ⏰ 4H | BEARISH | 37 |
| 🕐 1H | BEARISH | 98 |
| ⏱ 15-Min | BULLISH | 130 |
| ⏲ 5-Min | BEARISH | 234 |
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.